O R O G E N

Orogen announces appointment of director and \$2.7 million private placement

Vancouver, B.C. February 10, 2021 (TSX-V:OGN) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that Mr. J. Patrick Nicol, the Company's current President and Chief Executive Officer, has been appointed to the Board of Directors.

Orogen is also pleased to announce that Cranberry Capital Inc., an investment company controlled by Mr. Paul van Eeden, Chairman of the Board of Directors, has agreed to an investment of \$2.7 million in the Company. Upon the closing of the private placement, Mr. van Eeden will be the beneficial owner of approximately 14.9% of the Company on a partially diluted basis.

Cranberry Capital will subscribe for 10,000,000 units (the "Units") at a price of \$0.27 per Unit. Each Unit consists of one common share of the Company and one share purchase warrant (the "Warrants"). Each Warrant is exercisable into one common share of the Company at a price of \$0.40 for period of five years. No commissions or fees will be paid in connection with the private placement.

Cranberry Capital's investment is considered a related party transaction within the meaning of Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions* ("MI 61-101"). The Company intends to rely on an exemption from the valuation and minority shareholder approval requirements of MI 61-101 contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of Cranberry Capital's investment. The exemption is based on the fact that the market value of Cranberry Capital's investment does not exceed 25% of the market value of the Company.

The Company also granted nine million stock options with an exercise price of \$0.35 per share that vest over four years. The options have a duration of ten years.

The foregoing is subject to regulatory approval by the TSX Venture Exchange.

About Orogen Royalties

Orogen Royalties Inc. is engaged in project generation for precious and base metal deposits in western North America with a focus on organic royalty creation and royalty acquisitions. Orogen's royalty portfolio includes the Ermitaño West gold deposit in Sonora, Mexico (2% NSR) being developed by First Majestic Silver Corp. and the Silicon gold project (1% NSR) in Nevada, USA, being advanced by AngloGold Ashanti N.A. The Company is well financed with several projects actively being developed by joint venture partners.

On Behalf of the Board **OROGEN ROYALTIES INC.**

Paddy Nicol
President & CEO

To find out more about Orogen, please contact Paddy Nicol, President & CEO at 604-248-8648, and Liliana Wong, Manager of Marketing and Investor Relations at 604-248-8648. Visit our website at www.orogenroyalties.com.

Orogen Royalties Inc. 1201 - 510 West Hastings Street Vancouver, BC Canada V6B 1L8 info@orogenroyalties.com

Forward Looking Information

This news release includes certain statements that may be deemed "forward looking statements". All statements in this presentation, other than statements of historical facts, that address events or developments that Orogen Royalties Inc. (the "Company") expect to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur.

Forward looking information relates to statements concerning the Company's future outlook and anticipated events or results, as well as the Company's management expectations with respect to the proposed business combination (the "Transaction"). This document also contains forward-looking statements regarding the anticipated completion of the Transaction and timing thereof. Forward-looking statements in this document are based on certain key expectations and assumptions made by the Company, including expectations and assumptions concerning the receipt, in a timely manner, of regulatory and stock exchange approvals in respect of the Transaction.

Although the Company believe the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward looking statements. Factors that could cause the actual results to differ materially from those in forward looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. Furthermore, the extent to which COVID-19 may impact the Company's business will depend on future developments such as the geographic spread of the disease, the duration of the outbreak, travel restrictions, physical distancing, business closures or business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease. Although it is not possible to reliably estimate the length or severity of these developments and their financial impact as of the date of approval of these condensed interim consolidated financial statements, continuation of the prevailing conditions could have a significant adverse impact on the Company's financial position and results of operations for future periods.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by securities laws, the Company undertakes no obligation to update these forward looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.